Roche Q1 sales up 10%, confirms 2022 outlook

[April 25, 2022]  By Ludwig Burger

(Reuters) -Swiss drugmaker Roche's first quarter sales rose a better-than-expected 10% on strong U.S. demand for rapid COVID-19 antigen tests and drugs including Ocrevus against multiple sclerosis as well as Hemlibra against haemophilia.

Quarterly sales rose to 16.44 billion Swiss francs ($17.17 billion), up from 14.93 billion Swiss francs in the year-earlier period, the company said on Monday. That was slightly above a market consensus of about 16 billion francs.

The diagnostics division accounted for most of the positive surprise, reporting sales growth of 24% to 5.3 billion francs on usage of its COVID-19 tests and cardiac tests.

Roche reiterated that it expected currency-adjusted 2022 sales to be flat or grow in the low-single-digit percentage range, below last year's 9% gain.
 

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann

It also reaffirmed that sales of COVID-19 medicines and diagnostics would decrease by about 2 billion Swiss francs this year to around 5 billion francs.

Ocrevus revenue gained 18% to reach 1.45 billion francs and Hemlibra sales jumped 30% to 853 million francs, offsetting a decline in established off-patent cancer medicines Herceptin, Avastin and Rituxan due to cheaper rival products.

($1 = 0.9577 Swiss francs)

(Reporting by Ludwig BurgerEditing by Miranda Murray)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.